. 2023 Jan 25;14:1013958. doi: 10.3389/fphar.2023.1013958

TABLE 1.

General information provided in the included studies——systemic medication.

Study	Design	Age	Inclusion criteria		Intervention	The mode of administration (dose, time)	Following-up	Assessment
Study	Design	M/F	HbA1c	PD	Intervention	The mode of administration (dose, time)	Following-up	Assessment
2021 Cruz	RCT	Test: 60.5 ± 7.6 N = 5/10	6.5%–11%	PD ≥ 4 mm	Test: SRP + MTZ + AMX	MTZ 400 mg tid	2 years, 5 years	PD
		Control: 59.6 ± 6.6 N = 2/8			Control: SRP + placebo	AMX 500 mg tid		BOP
						14 days		CAL
						14 days		Microorganisms
2016 Tamashiro	RCT	Test: N = 29	≥6.5%	PD ≥ 5 mm	Test: SRP + MTZ + AMX	MTZ 400 mg tid	3 months, 1 year, 2 years	Microorganisms
		Control: N = 27			Control: SPR + placebo	AMX 500 mg tid
						14 days
2014 Miranda	RCT	Test: 54.0 ± 8.2 N = 29	6.5%–11%	PD ≥ 4 mm	Test: SRP + MTZ + AMX	MTZ 400 mg tid	3 months, 6 months, 12 months	PD
		Control: 53.7 ± 8.0 N = 27			Control: SPR + placebo	AMX 500 mg tid		BOP
						14 days		CAL
								HbA1c
								Microorganisms
2014 Tsalikis	RCT	Test: 62.9 ± 10 N = 18/13	<7.5%	PD ≥ 5 mm	Test: SRP + Doxy	Doxy 200 mg as loading dose and 100 mg for 20 days	3 months, 6 months	PD
		Control: 57.94 ± 8.22 N = 20/15			Control: SRP			BOP
								CAL
								HbA1c
								Microorganisms
2014 Hincapié	RCT	Test: 55.9 ± 12.6 N = 11/22	NA	PD ≥ 4 mm	Test: SRP + AZM	AZM 500 mg/3 d	3 months, 6 months, 9 months	HbA1c
T1MD + T2MD	RCT	Control: 58.2 ± 11.1 N = 10/27	NA	PD ≥ 4 mm	Control: SRP + placebo	AZM 500 mg/3 d	3 months, 6 months, 9 months	Microorganisms
2014 Javed	RCT	Test: 40.7 ± 1.2 N = 33/0	5.7%–6.4%	PD ≥ 5 mm	Test: SRP + Doxy	Doxy 100 mg/d 15 d	3 months	HbA1c
T1MD + T2MD	RCT	Control: 44.2 ± 1.4 N = 33/0	5.7%–6.4%	PD ≥ 5 mm	Control: SRP	Doxy 100 mg/d 15 d	3 months	CAL
2014 Al-Nowaiser	RCT	M/F = 47/21 age: 42 ± 6.41	5.8%–10%	PD ≥ 5 mm	Test: SRP + Doxy	Doxy 200 mg as loading dose and 100 mg for 14 days	1 month, 3 months, 6 months	PD
		Test: N = 35			Control: SRP			BOP
		Control: N = 33						CAL
		Control: N = 33						Microorganisms
2013 Botero	RCT	Test:55.9 ± 12.6 N = 11/22	NA	PD ≥ 5 mm	Test: SRP + AZM	AZM 500 mg/d 3 days	3 months, 6 months, 9 months	PD
T1MD + T2MD		Control:58.2 ± 11.1 N = 10/27			Control: SRP + placebo			BOP
								CAL
								HbA1c

SRP, scaling and root planning; MTZ, Metronidazole; AMX, Amoxicillin Doxy, Doxycycline; AZM, azithromycin.